Summary
Parkinson’s Disease (PD) is caused by dopaminergic neuron loss resulting in motor symptoms that are treated with L-DOPA.
However, ≤90% of patients develop involuntary movements, termed L-DOPA induced dyskinesia (LID). Another less well studied, but
highly occurring PD symptom is depression.
There is evidence that the serotonin system is implicated in both, LID and PD-linked depression. Serotonergic (5-HT) neurons
uncontrollably release L-DOPA-derived dopamine, and HTR1a/b agonists counteract such release and LIDs. Serotonin re-uptake
inhibitors (SSRIs) also attenuate LID, through a still unknown mechanism. The striatally enriched Gαs-coupled receptor, HTR4, has the
potential to enhance excitability of spiny projection neurons, to affect the balance of striatal pathways that is disrupted in PD and is a
candidate to modulate LID and PD-depression.
D2 agonists reduce depressive behavior in PD models, pointing towards a role for the striatum. Specifically, the dorsolateral striatum
shows diminished metabolism, in contrast to non-PD-depression where the ventral striatum is a substrate. HTR4 in cortex and
hippocampus was linked to antidepressant action. Agonists and overexpression yield anti-depressant-like responses, however,
striatal HTR4 in PD-depression has not been examined.
1. We will determine HTR4 protein expression on a cellular level (dSPNs, iSPNs) in transgenic mice. We will virally overexpress,
knockdown and pharmacologically manipulate HTR4 and assess striatally-driven behaviors.
2. We will probe HTR4 in motor symptoms by altering expression/activity in unilaterally 6-OHDA lesioned mice. We will evaluate LID
onset/severity, dyskinesia markers and LTP, depotentiation and LTD.
3. We will test bilaterally-lesioned mice with altered HTR4 expression/activity in depression/anxiety paradigms. We will determine
the effect on the action of D2, HTR1a agonists and SSRIs.
Our comprehensive investigation of HTR4 will lead to a new understanding and treatment of PD.
However, ≤90% of patients develop involuntary movements, termed L-DOPA induced dyskinesia (LID). Another less well studied, but
highly occurring PD symptom is depression.
There is evidence that the serotonin system is implicated in both, LID and PD-linked depression. Serotonergic (5-HT) neurons
uncontrollably release L-DOPA-derived dopamine, and HTR1a/b agonists counteract such release and LIDs. Serotonin re-uptake
inhibitors (SSRIs) also attenuate LID, through a still unknown mechanism. The striatally enriched Gαs-coupled receptor, HTR4, has the
potential to enhance excitability of spiny projection neurons, to affect the balance of striatal pathways that is disrupted in PD and is a
candidate to modulate LID and PD-depression.
D2 agonists reduce depressive behavior in PD models, pointing towards a role for the striatum. Specifically, the dorsolateral striatum
shows diminished metabolism, in contrast to non-PD-depression where the ventral striatum is a substrate. HTR4 in cortex and
hippocampus was linked to antidepressant action. Agonists and overexpression yield anti-depressant-like responses, however,
striatal HTR4 in PD-depression has not been examined.
1. We will determine HTR4 protein expression on a cellular level (dSPNs, iSPNs) in transgenic mice. We will virally overexpress,
knockdown and pharmacologically manipulate HTR4 and assess striatally-driven behaviors.
2. We will probe HTR4 in motor symptoms by altering expression/activity in unilaterally 6-OHDA lesioned mice. We will evaluate LID
onset/severity, dyskinesia markers and LTP, depotentiation and LTD.
3. We will test bilaterally-lesioned mice with altered HTR4 expression/activity in depression/anxiety paradigms. We will determine
the effect on the action of D2, HTR1a agonists and SSRIs.
Our comprehensive investigation of HTR4 will lead to a new understanding and treatment of PD.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/894207 |
Start date: | 01-01-2021 |
End date: | 31-12-2023 |
Total budget - Public funding: | 295 061,76 Euro - 295 061,00 Euro |
Cordis data
Original description
Parkinson’s Disease (PD) is caused by dopaminergic neuron loss resulting in motor symptoms that are treated with L-DOPA.However, ≤90% of patients develop involuntary movements, termed L-DOPA induced dyskinesia (LID). Another less well studied, but
highly occurring PD symptom is depression.
There is evidence that the serotonin system is implicated in both, LID and PD-linked depression. Serotonergic (5-HT) neurons
uncontrollably release L-DOPA-derived dopamine, and HTR1a/b agonists counteract such release and LIDs. Serotonin re-uptake
inhibitors (SSRIs) also attenuate LID, through a still unknown mechanism. The striatally enriched Gαs-coupled receptor, HTR4, has the
potential to enhance excitability of spiny projection neurons, to affect the balance of striatal pathways that is disrupted in PD and is a
candidate to modulate LID and PD-depression.
D2 agonists reduce depressive behavior in PD models, pointing towards a role for the striatum. Specifically, the dorsolateral striatum
shows diminished metabolism, in contrast to non-PD-depression where the ventral striatum is a substrate. HTR4 in cortex and
hippocampus was linked to antidepressant action. Agonists and overexpression yield anti-depressant-like responses, however,
striatal HTR4 in PD-depression has not been examined.
1. We will determine HTR4 protein expression on a cellular level (dSPNs, iSPNs) in transgenic mice. We will virally overexpress,
knockdown and pharmacologically manipulate HTR4 and assess striatally-driven behaviors.
2. We will probe HTR4 in motor symptoms by altering expression/activity in unilaterally 6-OHDA lesioned mice. We will evaluate LID
onset/severity, dyskinesia markers and LTP, depotentiation and LTD.
3. We will test bilaterally-lesioned mice with altered HTR4 expression/activity in depression/anxiety paradigms. We will determine
the effect on the action of D2, HTR1a agonists and SSRIs.
Our comprehensive investigation of HTR4 will lead to a new understanding and treatment of PD.
Status
SIGNEDCall topic
MSCA-IF-2019Update Date
28-04-2024
Images
No images available.
Geographical location(s)